Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3669-3675

  Chang, Yoon Soo ^a   Wang, Luo ^a   Liu, Diane ^a   Mao, Li ^a   Ki Hong, Waun ^a   Khuri, Fadlo R ^a   Lee, Ho Young ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGE; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CELL DIFFERENTIATION; CELL PROLIFERATION; CIRCULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; GENE EXPRESSION; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; MOLECULAR BIOLOGY; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SMOKING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TIME;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; DNA METHYLATION; DNA PRIMERS; DNA, NEOPLASM; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); SMOKING; SURVIVAL RATE;

EID: 0036894939     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Ginsberg, R. J., Vokes, E. E., and Raben, A. Non-small cell lung cancer. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 855-911. Philadelphia-New York: Lippincott-Raven, 1997.
2. Vogelstein, B., and Kinzler, K. W. The multistep nature of cancer. Trends Genet., 9: 138-141, 1993.
3. Robertson, K. D. DNA methylation, methyltransferases and cancer. Oncogene. 20: 3139-3155, 2001.
4. Tate, P. H., and Bird, A. P. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev., 3: 226-231, 1993.
5. Zochbauer-Muller, S., Fong, K. M., Virmani, A. K., Geradts, J., Gazdar, A. F., and Minna J. D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res., 61: 249-255, 2001.
6. Boyes, J., and Bird, A. Repression of genes by DNA methylation depends on CpG density and promoter strength: Evidence for involvement of a methyl-CpG binding protein. EMBO J., 11: 327-333, 1992.
7. 2 recruit histone deacetylase to repress transcription. Nat. Genet., 19: 187-191, 1998.
8. Stewart, C. E., and Rotwein, P. Growth, differentiation and survival: Multiple physiological functions for insulin-like growth factors. Physiol. Rev., 76: 1005-1026, 1996.
9. Jones, J. I., and Clemmons, D. R. Insulin-like growth factors and their binding proteins: Biological actions. Endocrinol. Rev., 16: 3-34, 1995.
10. Baxter, R. C. Signaling pathways involved in antiproliferative effects of insulin-like growth factor binding protein-3. J. Clin. Pathol. Mol. Pathol., 54: 145-148, 2001.
11. Lee, H-Y., Chun, K-H., Liu, B., Wiehle, S. A., Cristiano, R. J., Hong, W. K., Cohen, P., and Kurie, J. M. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res. 62: 3530-3537, 2002.
12. Yu, H., Spitz, M. R., Mistry, J., Gu, J., Hong, W. K., and Wu, X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst. (Bethesda), 91: 151-156, 1999.
13. Oh, Y., Muller, H. L., Lamson, G., and Rosenfeld, R. G. Insulin-like growth factor-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J. Biol. Chem., 268: 14964-14971, 1993.
14. Rajah, R., Valentinis, B., and Cohen, P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-b1 on programmed cell death through a p53-and IGF-independent mechanism. J. Biol. Chem., 272: 12181-12188, 1997.
15. Hochscheid, R., Jaques, G., and Wegmann, B. Transfection of human insulin-like growth factor-binding protein-3 gene inhibits cell growth and tumorigenicity: A cell culture model for lung cancer. J. Endocrinol., 166: 553-563, 2000.
16. Oh, Y., Muller, H. L., Ng, L., and Rosenfeld, R. G. Transforming growth factor-β induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J. Biol. Chem., 270: 13589-13592, 1995.
17. Rozen, F., Ahang, J., and Pollak, M. Antiproliferative action of tumor necrosis factor-α on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int. J Oncol., 13: 865-869, 1998.
18. Shang, Y., Baumrucker, C. R., and Green, M. H. Signal relay by retinoic acid receptors α and β in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells. J. Biol. Chem., 274: 18005-18010, 1999.
19. Huynh, H., Nickerson, T., Pollak, M., and Yang, X. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI182780. Clin. Cancer Res., 2: 2037-2042, 1996.
20. 3 and its analog EB1089. Int. J. Oncol., 13: 137-143, 1998.
21. Agarwal, C., Lambert, A., Chandraratna, R. A. S., Rorke, E. A., and Eckert, R. L. Vitamin D regulates human ectocervical epithelial cell proliferation and insulin-like growth factor binding protein-3 level. Biol. Reprod., 60: 567-572, 1999.
22. Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., and Kley, N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature (Lond.), 377: 646-649, 1995.
23. Deal, C., Ma, J., Wilkin, O., Paquette, J., Rozen, F., Ge, B., Hudson, T., Stampfer, M., and Pollak, M. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: Correlation with serum levels and interaction with known regulators. J. Clin. Endocrinol. Metab., 86: 1274-1280, 2001.
24. Hanafusa, T., Yumoto, Y., Nouso, K., Nakatsukasa, H., Onishi, T., Fujikawa, T., Taniyama, M., Nakamura, S., Uemura, M., Takuma, Y., Yumoto, E., Higashi, T., and Tsuji, T. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett., 176: 149-158, 2002.
25. Soria, J. C., Lee, H. Y., Lee, J. I., Wang, L., Issa, J. P., Kemp, B. L., Liu, D. D., Kurie, J. M., Mao, L., and Khuri, F. R. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res., 8: 1178-1184, 2002.
26. Khuri, F. R., Wu, H., Lee, J. J., Kemp, B. L., Lotan, R., Lippman, S. M., Feng, L., Hong, W. K., and Xu, X. C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res., 7: 861-867, 2001.
27. Soria, J. C., Jang, S. J., Khuri, F. R., Hassan, K., Liu, D., Hong, W. K., and Mao, L. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res., 60: 4000-4004, 2000.
28. Khuri, F. R., Lotan, R., Kemp, B. L., Lippman, S. M., Wu, H., Feng, L., Lee, J. J., Cooksley, C. S., Parr, B., Chang, E., Walsh, G. L., Lee, J. S., Hong, W. K., and Xu, X. C. Retinoic acid receptor-β as a prognostic indicator in stage I non-small-cell lung cancer. J. Clin. Oncol., 18: 2798-2804, 2000.
29. Herbst, R. S., Yano, S., Kuniyasu, H., Khuri, F. R., Bucana, C. D., Guo, F., Liu, D., Kemp, B., Lee, J. J., Hong, W. K., and Fidler, I. J. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin. Cancer Res., 6: 790-797, 2000.
30. Zhou, X., Kemp, B. L., Khuri, F. R., Liu, D., Lee, J. J., Wu, W., Hong, W. K., and Mao, L. Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clin. Cancer Res., 6: 559-565, 2000.
31. Tseng, J. E., Kemp, B. L., Khuri, F. R., Kurie, J. M., Lee, J. S., Zhou, X., Liu, D., Hong, W. K., and Mao, L. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res., 59: 4798-4803, 1999.
32. Tang, X., Khuri, F. R., Lee, J. J., Kemp, B. L., Liu, D., Hong, W. K., and Mao, L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. (Bethesda), 92: 1511-1516, 2000.
33. Kim, S. K., Ro, J. Y., Kemp, B. L., Lee, J. S., Kwon, T. J., Fong, K. M., Sekido, Y., Minna, J. D., Hong, W. K., and Mao, L. Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. Cancer Res., 57: 400-403, 1997.
34. Mao, L., Lee. J. S., Fan, Y. H., Ro, J. Y., Batsakis, J. G., Lippman, S., Hittelman, W., and Hong, W. K. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat. Med., 2: 682-685, 1996.
35. Herman, J. G., Graff, J. R., Myohanen, S., Hamilton, S. R., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
36. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-29. 1998.
37. Mountain, C. F. Value of the new TNM staging system for lung cancer. Chest, 96 (Suppl.); 47S-49S, 1997.
38. Baylin, S. B., and Herman, J. G. DNA hypermethylation in tumor-igenesis: Epigenetics joins genetics. Trends Genet., 16: 168-174, 2000.
39. Jones, P. A., and Laird, P. W. Cancer epigenetics comes of age. Nat. Genet., 21: 163-167, 1999.
40. Robertson, K. D. DNA methylation, methyltransferases, and cancer. Oncogene, 20: 3139-3155, 2001.
41. Piyathilake, C. J., Frost, A. R., Bell, W. C., Oelschlager, D., Weiss, H., Johanning, G. L., Niveleau, A., Heimburger, D. C., and Grizzle, W. E. Altered global methylation of DNA: An epigenetic difference in susceptibility for lung cancer is associated with its progression. Hum. Pathol, 32: 856-862, 2001.
42. Chang, Y. S., Gong, K., Sun, S., Liu, D., El-Naggar, A. K., Khuri, F. R., Hong, W. K., and Lee, H-Y. Clinical significance of IGFBP-3 expression in stage I non-small cell lung cancer. Clin. Cancer Res., 8: 3796-3802, 2002.
43. INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res., 61: 3419-3424, 2001.
44. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation (20%) is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
45. Kashiwabara, K., Oyama, T., Sano, T., Fukuda, T., and Nakajima, T. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int. J. Cancer, 79: 215-220, 1998.
46. Baserga, R. The IGF-I receptor in cancer research. Exp. Cell Res., 253: 1-6, 1999.
47. Gatzka, M., Prisco, M., and Baserga, R. Stabilization of the Ras oncoprotein by the insulin-like growth factor I receptor during anchor-age-independent growth. Cancer Res., 60: 4222-4230, 2000.
48. D'Ambrosio, C., Ferber, A., Resnicoff, M., and Baserga, R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res., 56: 4013-4020, 1996.
49. Resnicoff, M., Sell, C., Rubini, M., Coppola, D., Ambrose, D., Baserga, R., and Rubin, R. Rat glioblastoma cells expressing an anti-sense RNA to the insulin-like growth factor I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res., 54: 2218-2222, 1994.